Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 5/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CIT | O14578 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036267 | 0.99 | METAP2 (0.35) | METAP2NAAARENCTSCAAK1 | |
| SCHEMBL7039308 | 0.91 | METAP2 (0.33) | METAP2NAAARENCTSCAAK1 | |
| SCHEMBL7037265 | 0.90 | METAP2 (0.34) | METAP2NAAARENCTSCAAK1 | |
| SCHEMBL7037428 | 0.84 | AAK1 (0.35) | METAP2NAAACTSCAAK1METAP1 | |
| SCHEMBL7034077 | 0.83 | AAK1 (0.37) | METAP2NAAACTSCAAK1METAP1 | |
| SCHEMBL6486130 | 0.78 | CTSK (0.52) | CTSKCTSS | |
| SCHEMBL6486137 | 0.78 | CTSK (0.52) | CTSKCTSS | |
| SCHEMBL6485762 | 0.78 | CTSK (0.53) | CTSKCTSS | |
| SCHEMBL6485772 | 0.78 | CTSK (0.53) | CTSKCTSS | |
| SCHEMBL6515339 | 0.77 | CTSL (0.42) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | claimed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | METAP2 531/4885NAAA 2748/4885REN 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.